Detalles de la búsqueda
1.
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Lancet Oncol
; 17(2): 234-242, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26708155
2.
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting.
JCO Precis Oncol
; 8: e2300334, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271655
3.
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Lung Cancer
; 188: 107442, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38171156
4.
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Thyroid
; 34(1): 26-40, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38009200
5.
Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC.
JTO Clin Res Rep
; 3(7): 100341, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35756755
6.
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Clin Cancer Res
; 28(9): 1800-1808, 2022 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35275991
7.
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
CPT Pharmacometrics Syst Pharmacol
; 10(11): 1357-1370, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34547184
8.
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
J Thorac Oncol
; 15(4): 601-608, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31712133
9.
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
Lung Cancer
; 139: 22-27, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31706099
10.
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
J Thorac Oncol
; 14(7): 1233-1243, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30902613
11.
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib.
J Comp Eff Res
; 7(9): 855-865, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29944008
12.
Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Cancer Chemother Pharmacol
; 82(1): 129-138, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29748847
13.
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer.
ESMO Open
; 3(5): e000364, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30018815
14.
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Clin Pharmacol Drug Dev
; 6(3): 280-291, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27545757
15.
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
Cancer Chemother Pharmacol
; 79(3): 559-568, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28243683
16.
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Eur J Cancer
; 82: 27-33, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28646771
17.
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
J Thorac Oncol
; 12(10): 1552-1560, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28689043
18.
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Cancer Chemother Pharmacol
; 77(3): 623-8, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26849637
19.
Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.
Clin Pharmacol Ther
; 110(5): 1162-1163, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34365647
20.
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
J Clin Oncol
; 34(7): 661-8, 2016 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26598747